Search
Now showing items 41-50 of 90
Calibration of CTS5 in Women With Early Estrogen Receptor-Positive Breast Cancer.
(American Society of Clinical Oncology, 2020-12-16)
Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®.
(Nature Research, 2021-02-12)
Multi-gene prognostic signatures including the Oncotype® DX Recurrence Score (RS), EndoPredict® (EP) and Prosigna® (Risk Of Recurrence, ROR) are widely used to predict the likelihood of distant recurrence in patients with ...
Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial.
(2021-01-22)
BACKGROUND: Anastrozole has been associated with substantial accelerated bone mineral density (BMD) loss during active treatment. METHODS: One thousand four hundred and ten women were included in a BMD substudy and stratified ...
The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies
(Springer Nature, 2021-03-03)
Background We investigated the association between body mass index (BMI) and breast cancer risk in women at increased
risk of breast cancer receiving tamoxifen or anastrozole compared with placebo using data from the ...
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial (vol 395, pg 117, 2020)
(2021-02-27)
Correction to Cuzick J, Sestak I, Forbes JF, et al. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet 2020; 395: 117–22—In this Article, Bernardo Bonanni's ...
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
(Elsevier, 2017-12-11)
Background Neoadjuvant chemotherapy (NACT) for early breast cancer can make breast-conserving surgery more
feasible and might be more likely to eradicate micrometastatic disease than might the same chemotherapy given ...